Identification of Polyoxometalates as Nanomolar Noncompetitive Inhibitors of Protein Kinase CK2

Chemistry and Biology

Volumn 15, Issue 7, 2008, Pages 683-692

  Prudent, Renaud ^a   Moucadel, Virginie ^a   Laudet, Béatrice ^a   Barette, Caroline ^a   Lafanechère, Laurence ^a   Hasenknopf, Bernold ^b   Li, Joaquim ^b   Bareyt, Sébastian ^b   Lacôte, Emmanuel ^b   Thorimbert, Serge ^b   Malacria, Max ^b   Gouzerh, Pierre ^b   Cochet, Claude ^a  

^a CEA GRENOBLE   (France)

^b CNRS   (France)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASEIN KINASE II; PEPTIDE; POLYOXOMETALATE I; PROTEIN KINASE INHIBITOR; TUNGSTEN DERIVATIVE;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; HUMAN; IC 50; METHODOLOGY; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CASEIN KINASE II; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PEPTIDES; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TUNGSTEN COMPOUNDS;

EID: 46849092572     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.05.018     Document Type: Article

References (49)

1. Ahmed K., Gerber D.A., and Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 12 (2002) 226-230
2. Aureliano M., and Gandara R.M.C. Decavanadate effects in biological systems. J. Inorg. Biochem. 99 (2005) 979-985
3. Bareyt S., Piligkos S., Hasenknopf B., Gouzerh P., Lacôte E., Thorimbert S., and Malacria M. Highly efficient peptide bond formation to functionalized Wells-Dawson-type polyoxotungstates. Angew. Chem. Int. Ed. 42 (2003) 3404-3406
4. Bareyt S., Piligkos S., Hasenknopf B., Gouzerh P., Lacote E., Thorimbert S., and Malacria M. Efficient preparation of functionalized hybrid organic/inorganic Wells-Dawson-type polyoxotungstates. J. Am. Chem. Soc. 127 (2005) 6788-6794
5. 31P NMR spectroscopy. J. Alloy. Comp. 249 (1997) 56-68
6. 6- in aqueous media. J. Mater. Chem. 12 (2002) 299-304
7. Bogoyevitch M.A., and Fairlie D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12 (2007) 622-633
8. Crans D.C. Interactions of oxovanadates and selected oxomolybdates with enzymes. Mol. Eng. 3 (1993) 277-284
9. 2O, a new lacunary polyoxotungstophosphate. Can. J. Chem. 65 (1987) 568-573
10. Contant R. Potassium octadecatungstodiphosphates(V) and related lacunary compounds. Inorg. Synth. 27 (1990) 104-111
11. Filhol O., Cochet C., Wedegaertner P., Gill G.N., and Chambaz E.M. Coexpression of both α and β subunits is required for assembly of regulated casein kinase II. Biochemistry 30 (1991) 11133-11140
12. Filhol O., Nueda A., Martel V., Gerber-Scokaert D., Benitez M.J., Souchier C., Saoudi Y., and Cochet C. Live-cell fluorescence imaging reveals the dynamics of protein kinase CK2 individual subunits. Mol. Cell. Biol. 3 (2003) 975-987
13. Hasenknopf B. Polyoxometalates: introduction to a class of inorganic compounds and their biomedical applications. Front. Biosci. 10 (2005) 275-287
14. Heriche J.K., Lebrin F., Rabilloud T., Leroy D., Chambaz E.M., and Goldberg Y. Regulation of protein phosphatase 2A by direct interaction with casein kinase 2α. Science 276 (1997) 952-955
15. Hervé M., Sinoussi-Barre F., Chermann J.C., Hervé G., and Jasmin C. Correlation between structure of polyoxotungstates and their inhibitory activity on polymerases. Biochem. Biophys. Res. Commun. 116 (1983) 222-229
16. Hill C.L., Weeks M.S., and Schinazi R.F. Anti-HIV-1 activity, toxicity, and stability studies of representative structural families of polyoxometalates. J. Med. Chem. 33 (1990) 2767-2772
17. Himeno S., Hashimoto M., and Ueda T. Formation and conversion of molybdophosphate and arsenate complexes in aqueous solution. Inorg. Chim. Acta 284 (1999) 237-245
18. 12-: an investigation of the key variables in its synthesis plus multiple control reactions leading to a reliable synthesis. Inorg. Chem. 41 (2002) 2720-2730
19. Hu D., Shao C., Guan W., Su Z., and Sun J. Studies on the interactions of Ti-containing polyoxometalates (POMs) with SARS-CoV 3CLpro by molecular modeling. J. Inorg. Biochem. 101 (2007) 89-94
20. Judd D.A., Nettles J.H., Nevins N., Snyder J.P., Liotta D.C., Tang J., Ermolieff J., Schinazi R.F., and Hill C.L. Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J. Am. Chem. Soc. 123 (2001) 886-897
21. Kim J.S., Eom J.I., Cheong J.W., Choi A.J., Lee J.K., Yang W.I., and Min Y.H. Protein kinase CK2α as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin. Cancer Res. 13 (2007) 1019-1028
22. Klemperer W.G. Tetrabutylammonium isopolyoxometalates. Inorg. Synth. 27 (1990) 71-85
23. Laramas M., Pasquier D., Filhol O., Ringeisen F., Descotes J.L., and Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2α) is associated with poor prognostic factors in human prostate cancer. Eur. J. Cancer 43 (2007) 928-934
24. Lee I.S., Long J.R., Prusiner S.B., and Sfar J.G. Selective precipitation of prions by polyoxometalate complexes. J. Am. Chem. Soc. 127 (2005) 13802-13803
25. Litchfield D.W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369 (2003) 1-15
26. Meggio F., Pagano M.A., Moro S., Zagotto G., Ruzzene M., Sarno S., Cozza G., Bain J., Elliott M., Deana A.D., et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 43 (2004) 12931-12936
27. 2O, against, human gastric cancer model. Biomed. Pharmacother. 60 (2006) 353-358
28. Müller C.E., Iqbal J., Baqi Y., Zimmermann H., Röllich A., and Stephan H. Polyoxometalates-a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 5943-5947
29. Niefind K., Guerra B., Ermakowa I., and Issinger O.G. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 20 (2001) 5320-5331
30. Pagano M.A., Meggio F., Ruzzene M., Andrzejewska M., Kazimierczuk Z., and Pinna L.A. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 321 (2004) 1040-1044
31. Pagano M.A., Cesaro L., Meggio F., and Pinna L.A. Protein kinase CK2: a newcomer in the 'druggable kinome'. Biochem. Soc. Trans. 34 (2006) 1303-1306
32. 2-) system as deduced from a combined Emf-phosphorus-31 NMR study. Inorg. Chem. 25 (1986) 4726-4733
33. Pluskey S., Mahroof-Tahir M., Crans D.C., and Lawrence D.S. Vanadium oxoanions and cAMP-dependent protein kinase: an anti-substrate inhibitor. Biochem. J. 321 (1997) 333-339
34. Pope M.T. Introduction to polyoxometalate chemistry. In: Borras-Almenar J.J., Coronado E., Müller A., and Pope M.T. (Eds). Polyoxometalate Molecular Science Volume 98 (2003), Kluwer Academic Publishers, Dordrecht 3-31
35. Rhule J.T., Hill C.L., Judd D.A., and Schinazi R.F. Polyoxometalates in medicine. Chem. Rev. 98 (1998) 327-357
36. Ruhlmann L., Nadjo L., Canny J., Contant R., and Thouvenot R. Di- and tetranuclear Dawson-derived sandwich complexes: Synthesis, spectroscopic characterization, and electrochemical behavior. Eur. J. Inorg. Chem. (2002) 975-986
37. Sarafianos S.G., Kortz U., Pope M.T., and Modak M.J. Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft. Biochem. J. 319 (1996) 619-626
38. Sarno S., Ghisellini P., and Pinna L.A. Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. J. Biol. Chem. 277 (2002) 22509-22514
39. Sarno S., de-Moliner E., Ruzzene M., Pagano M.A., Battistutta R., Bain J., Fabbro D., Schoepfer J., Elliott M., Furet P., et al. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem. J. 374 (2003) 639-646
40. Sazani G., and Pope M.T. Organotin and organogermanium linkers for simple, direct functionalization of polyoxotungstates. Dalton Trans. Jul 7 (2004) 1989-1994
41. Schemberg J., Schneider K., Demmer U., Warkentin E., Müller A., and Ermler U. Towards biological supramolecular chemistry: a variety of pocket-templated, individual metal oxide cluster nucleations in the cavity of a Mo/W-storage protein. Angew. Chem. Int. Ed. Engl. 46 (2007) 2408-2413 and 2970
42. 39Co] on mitogenic activity of basic fibroblast growth factor. Chem. Lett. (Jpn.) 33 (2004) 298-299
43. Tajima Y. Anionic properties of polyoxometalates. Trends Inorg. Chem. 8 (2004) 107-117
44. Tawfic S., Yu S., Wang H., Faust R., Davis A., and Ahmed K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 16 (2001) 573-582
45. Valero E., Debonis S., Filhol O., Wade R.H., Langowski J., Chambaz E.M., and Cochet C. Quaternary structure of casein kinase-2 - characterization of multiple oligomeric states and relation with its catalytic activity. J. Biol. Chem. 270 (1995) 8345-8352
46. Vangrevelinghe E., Zimmermann K., Schoepfer J., Portmann R., Fabbro D., and Furet P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 46 (2003) 2656-2662
47. Williams D.S., Carroll P.J., and Meggers E. Platinum complex as a nanomolar protein kinase inhibitor. Inorg. Chem. 46 (2007) 2944-2946
48. Wu Q., Wang J., Zhang L., Hong A., and Ren J. Molecular recognition of basic fibroblast growth factor by polyoxometalates. Angew. Chem. Int. Ed. 44 (2005) 4048-4052
49. Yamase T. Anti-tumor, -viral, and -bacterial activities of polyoxometalates for realizing an inorganic drug. J. Mater. Chem. 15 (2005) 4773-4782